Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Immunity Cells in Blood

Innate Immunity Signal Transduction in Human Leukocytes

Studies Seeking Participants Icon Studies Seeking Participants Location icon Residents of North Carolina 18 - 65 Ages 18 - 65 Gender Icon All Genders
vials of a red substance in a vial holder.
  1. Home
  2. Studies
  3. Immunity Cells in Blood
  4. Study Overview

We protect our registrants' privacy

What Is the Response of Immune Cells From the Bloodstream?

The Immunity Cells in Blood Study will determine how immune cells in the bloodstream may, under certain circumstances, contribute to inflammation. To understand how blood responds to possible disease-related conditions, it will also measure substances in blood plasma, or the liquid, non-cellular part of the blood, which may stimulate white blood cells.

Who Can Participate?

  • Healthy men and non-pregnant women aged 18-65
  • Weighing at least 110 pounds

What Is Required?

  • Qualified participants that donate up to 320 ml of blood, approximately 1 1/3 cups, will receive $45 per donation
  • Each participant can donate up to every 8 weeks

Who Is Running the Study?

The Immunity Cells in Blood Study is conducted by the National Institute of Environmental Health Sciences (NIEHS), U.S. Department of Health and Human Services.

Lead Researcher

Michael B. Fessler, M.D.

Dr. Michael Fessler received his medical degree at Harvard Medical School in 1996, and followed this with internal medicine residency training at Massachusetts General Hospital and pulmonary/critical care medicine training at University of Colorado. While at University of Colorado as a physician scientist, Dr. Fessler developed expertise in research into the human immune system, focusing in particular on macrophages and neutrophils, white blood cells that protect the body from infection, but that can also cause damaging inflammation in the lungs and other organs. In 2006, Dr. Fessler moved to NIEHS to start his own laboratory, which conducts a wide range of basic (cell-based) and clinical (epidemiology, patient-based) studies that aim to identify mechanisms by which the immune system gets activated, and how we may intervene in its activation to treat or prevent lung diseases such as pneumonia, acute lung injury, and asthma.  As Acting Chief of the Immunity, Inflammation and Disease Laboratory at the NIEHS, he now oversees a department of research laboratories focused on the study of immune-mediated diseases.  In his own work, Dr. Fessler has identified variations in the DNA code that put patients at heightened risk of damaging inflammation, has identified a role for household dust bacteria in driving inflammation in healthy people, has discovered new ways by which high cholesterol causes inflammation, and has also identified new potential drugs for treating immune system overactivation.  His ongoing studies on immune cells collected at the NIEHS Clinical Research Unit, made possible by the generous participation of volunteer blood donors, ultimately aspire to advance our understanding and treatment of inflammatory diseases in humans.

Research Page

Stavros Garantziotis, M.D.

Stavros Garantziotis, M.D. is passionate about finding cures for chronic lung disease like asthma, COPD and pulmonary fibrosis. He believes that if we can understand the mechanism of disease development for every individual patient, we can design intelligent and effective treatment with less side effects. Dr. Garantziotis obtained his medical degree at the Albert-Ludwigs-University in Germany. He trained in Internal Medicine at the Albert Einstein College of Medicine in New York and in Pulmonary and Critical Care Medicine at Duke University Medical Center, where he was a faculty member before joining the NIEHS to direct the Clinical Research Unit.

Research Page

For More Information About This Study

This content is available to use on your website.

Please visit NIEHS Syndication to get started.